Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.878461DOI Listing

Publication Analysis

Top Keywords

absence braf
4
braf kras
4
kras hotspot
4
hotspot mutations
4
mutations primary
4
primary mediastinal
4
mediastinal b-cell
4
b-cell lymphoma
4
absence
1
kras
1

Similar Publications

Aim: Cutaneous adverse events (CAEs) after treatment with BRAF and MEK inhibitors in patients with melanoma remain incompletely characterized. To determine the association of BRAF and MEK inhibitor treatment with CAEs in patients with melanoma compared with BRAF inhibitor alone.

Method: PubMed, Cochrane, Embase and Web of Science were systematically searched for BRAF and MEK inhibitors from database inception through 10 May 2024.

View Article and Find Full Text PDF

Background: Craniopharyngiomas are epithelial tumors derived from the remnants of the Rathke pouch, while Rathke cleft cysts (RCC) are benign cystic lesions originating from the Rathke pouch itself [1]. Rathke cleft cysts comprise 10-15% of the hypophyseal tumors, while craniopharyngiomas are relatively rare, comprising only 2-5% of intracranial tumors [2]. Both located in the sellar and parasellar regions and share clinical symptoms including headache, visual disturbances, and endocrine dysfunction [3].

View Article and Find Full Text PDF

Patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) who fail first- and second-line treatments face significant challenges in third-line therapy, where monotherapies often yield poor outcomes and limited survival benefits. The prognosis is particularly poor for mCRC with the unique molecular subtype of BRAF V600E mutation. This report describes sustained benefits from a third-line treatment regimen (SFS) combining tegafur/gimeracil/oteracil (S-1), fruquintinib, and sintilimab in a patient with BRAF V600E-mutated MSS mCRC.

View Article and Find Full Text PDF

A Narrative Review of Molecular, Immunohistochemical and In-Situ Techniques in Dermatopathology.

Br J Biomed Sci

January 2025

St. John's Dermatopathology Laboratory, Synnovis Analytics, St. Thomas' Hospital, London, United Kingdom.

Article Synopsis
  • Skin disorders are a major global health issue, affecting millions and requiring improved understanding and treatment approaches.
  • Recent advancements in molecular techniques, like PCR and next-generation sequencing, have enhanced our ability to diagnose and treat these disorders accurately and effectively.
  • These technologies allow for precise identification of infectious agents, genetic mutations, and gene expression patterns, leading to personalized therapies and better management of conditions like skin cancer and infections.
View Article and Find Full Text PDF

Introduction: The transcriptomic characteristics of + non-small cell lung cancer (NSCLC) represent a crucial aspect of its tumor biology. These features provide valuable insights into key dysregulated pathways, potentially leading to the discovery of novel targetable alterations or biomarkers.

Methods: From The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases, all available + (n = 10), + (n = 5) and + (n = 5) NSCLC tumor and + cell line (n = 7) RNA-sequencing files were collected.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!